Correlation between COVID-19 vaccination and inflammatory musculoskeletal disorders: analysis of Korean National Health Insurance database

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 6, 2025

The aim of this study was to investigate the incidence rates inflammatory musculoskeletal disorders following COVID-19 vaccination and compare them with those in unvaccinated individuals. We used data from 2,218,715 individuals Korean National Health Insurance Service database investigated vaccination. At 12 weeks after vaccination, cumulative plantar fasciitis (0.14–0.17%), rotator cuff syndrome (0.29–0.42%), adhesive capsulitis (0.29–0.47%), HIVD (0.18–0.23%), spondylosis (0.14–0.23%), bursitis (0.02–0.03%), Achilles tendinitis (0.0–0.05%), de-Quervain tenosynovitis (0.04–0.05%) were higher all three vaccinated groups (mRNA vaccine, viral vector mixing matching) compared group. All vaccines identified as significant risk factors for (odds ratio, 1.404 3.730) except matching de Quervain tenosynovitis. This suggests a strong correlation between concerning adverse reactions.

Language: Английский

---

Cinnamon: health benefits and its potential role in prevention and treatment of COVID-19

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 263 - 288

Published: Jan. 1, 2025

Language: Английский

---

Report on adverse events of COVID-19 vaccines in Iran: a comprehensive national prospective longitudinal analysis

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 14, 2025

Introduction The global coronavirus disease 2019 (COVID-19) pandemic necessitated urgent vaccine development, raising concerns about potential adverse events (AEs). Methods In this prospective cohort study, conducted from February 2021 to December 2022, all individuals across Iran who received any COVID-19 dose and reported were investigated. Our aim was evaluate these AEs based on the types, patients’ age types of AES, provide a comprehensive analysis. Results Iran, 155 million doses administered, with Covilo (Sinopharm) being most commonly administered (80.35%). Adverse predominantly affected aged 40-70 (45%). A total 86,275 recorded, 92.7% classified as non-serious 6 299 (7.3%) serious among cases, 279 confirmed be vaccine-related, 46 resulting in fatalities 233 requiring hospitalizations. incidence 0.41 per 10,000 doses. Serious more frequently associated Sputnik V Vaxzevria (AstraZeneca), 0.73 0.64 cases injections, respectively. Coagulation thrombosis disorders common (29%), followed by neurological (24.7%) cardiovascular (15.8%). Discussion conclusion, vaccination primarily mild transient, while remained exceptionally rare.

Language: Английский

---

Adverse effect profile of COVID-19 vaccine in Northern Nigeria: a prospective observational study

Annals of African Medical Research, Journal Year: 2025, Volume and Issue: 8

Published: Feb. 18, 2025

In March 2021, the Nigerian Government approved Coronavirus 2019 (COVID-19) vaccines, including CHAd0x1 nCov-19, Ad26.Cov2.S, mRNA-1273 and BNT162b2. Many, healthcare workers, expressed hesitancy due to potential adverse effects. We conducted an observational study assess effects of post-vaccination. followed vaccinated unvaccinated cohorts daily for 7 days then weekly 3 weeks. compared between groups. Vaccinated participants were 21 times more likely experience effect (Relative Risk, RR=21.30; 95% Confidence Interval, 95%CI=8.107-56.012) 4 systemic (RR=3.97; 95%CI=1.70-9.27) when participants. Female significantly associated with development both local effects, X2=77.9% (p≤0.001) X2=47.1% (p=0.0037), respectively. Up 81.6% second-dose vaccine recipients 68.4% first-dose developed at least one effect, X2=5.25 (p=0.071). None severe during period. Adverse from COVID-19 vaccination are common, but generally safe tolerable. Females play a significant role in reporting Both expected resolve within few

Language: Английский

---

Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Feb. 19, 2025

To analyses real-world safety data of mRNA COVID-19 vaccines within the European Economic Area (EEA), using Individual Case Safety Reports (ICSR), and to evaluate variability in profiles between different vaccine versions. We utilized EudraVigilance from 1 January 2020, 31 December 2023, focusing on Moderna (Spikevax) Pfizer/BioNTech (Comirnaty) against COVID-19. performed descriptive statistics, co-occurrence analysis, correspondence analysis identify patterns clusters adverse events following immunization (AEFI). retrieved 993,199 ICSR (Moderna: 394,484; Pfizer: 605,794), with most reports related women patients (69%) non-healthcare professionals (65%). A total 10,804 distinct AEFI terms were described across ICSR, a cumulative occurrence frequency 3,558,219 1,555,638; 2,031,828). The prominent serious included headache, fatigue, pyrexia, myalgia, arthralgia, malaise, nausea, chills, which frequently co-occurred vaccination failure. Specific like fever, injection site pain, inflammation, warmth more often linked Moderna, while Pfizer was commonly associated failure, menstrual disorders (heavy bleeding dysmenorrhea), hypoesthesia. In older adults, confusional states, cerebrovascular accidents, myocardial infarctions, myocarditis pericarditis noted younger males. Although rare, systemic AEFI, anaphylactic reactions, identified but require further causality evaluation. overall for mass is supported, continuous pharmacovigilance remains essential. Identified particularly ones, although rare potentially influenced by other underlying causes, underscore need monitoring epidemiological investigations explore potential causal relationships.

Language: Английский

---

Self‐Reported Adverse Events Following COVID‐19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross‐Sectional Study

Health Science Reports, Journal Year: 2025, Volume and Issue: 8(3)

Published: March 1, 2025

Accurate and transparent investigation of adverse events (AEs) following COVID-19 vaccination enhances social trust confidence in programs. This study aimed to assess the prevalence vaccination-related AEs among medical sciences students. In this cross-sectional study, a self-administered survey via Google Forms was conducted evaluate associated with AZD1222 (Oxford-AstraZeneca) BBIBP-CorV (Sinopharm) vaccines Data were collected participation training program focused on symptomatology AEs, which designed reduce confirmation bias. A total 263 students from North Khorasan University Medical Sciences, Bojnurd, Iran, participated data collection occurring August 8 September 1, 2021. The median age population 23 years (IQR: 22-24), 207 participants being female (78.7%). Following first dose, significantly more common Oxford-AstraZeneca group compared Sinopharm [OR 12.93 (5.57-30.03), p < 0.001]. However, second there no significant difference between 1.45 (0.86-2.46), = 0.17]. Injection site pain, fever, body/muscle headache, feeling unwell, fatigue most both vaccines, variations doses. type vaccine sex only factors influencing AEs. Notably, odds experiencing higher women men. findings indicated that for vaccine. Further research is necessary explore impact utilizing standardized definitions terminology ensuring accurate consistent reporting.

Language: Английский

---

New-onset hematologic disorders following COVID-19 vaccination: a systematic review

Clinical and Experimental Vaccine Research, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 1, 2025

Coronavirus disease 2019 (COVID-19) vaccination reduced morbimortality rates due to severe acute respiratory syndrome coronavirus 2 infection worldwide. However, various complications have been reported, including hematologic disorders. We conducted a systematic review synthesize and analyze the current available evidence on development of hematological disorders associated with COVID-19 vaccination. A total 227 patients were reported in papers that selected be included. There was slight predominance females (n=114, 50.22%) compared males (n=113, 49.78%), calculated mean age 54.86±18.94 years. The most frequently Immune thrombocytopenic purpura (n=58, 25.55%), followed by thrombotic (n=38, 16.74%). less recorded cases acquired factor XIII/13 deficiency (n=2, 0.88%) pernicious anemia 0.88%). Messenger RNA (mRNA)-based vaccines, Pfizer BioNTech 162b2 (n=106, 46.70%), Moderna mRNA 127-3 (n = 42, 18.50%), Bivalent vaccine 1, 0.44%), prevalent (n=150, 66.08%). Most developed after first dose (n=120, 52.86%). In cases, patient outcomes favorable (n=175, 77.09%), but there significant mortality (n=23, 10.13%). Our findings suggest close monitoring who receive technology regardless sex, especially adults, as they appear more vulnerable developing PROSPERO Identifier: CRD42023452589.

Language: Английский

---

Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials

Expert Review of Vaccines, Journal Year: 2025, Volume and Issue: 24(1), P. 339 - 349

Published: May 7, 2025

Evidence regarding the comparative safety of different COVID-19 vaccines remains limited. This study aims to characterize and compare profiles five in terms adverse reactions after immunization. We conducted a retrospective analysis reported among adults aged 18-59 years from nine clinical trials. The analyzed included inactivated, recombinant protein, intranasal influenza-vectored, aerosolized intramuscular Ad5 vectored vaccines. Factor association rule were used reaction patterns, while multivariate logistic regression was employed assess influence vaccine type demographic factors. Inactivated, recombinant, commonly caused injection site pain, fatigue, headache, pyrexia SOC 'General disorders administration conditions.' Intranasal influenza-vectored mainly cause respiratory symptoms such as rhinorrhea nasal congestion, dry mouth oropharyngeal pain 'Gastrointestinal disorders' primarily observed Younger age (p < 0.001), female sex = comorbidities 0.001) significantly associated with higher risks. developed through technological approaches have distinct profiles.

Language: Английский

---

Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 12, 2025

Introduction The emergence of SARS-CoV-2 variants concern (VOCs), particularly Omicron, has challenged the efficacy initial COVID-19 vaccination strategies. Booster immunizations, especially with mRNA vaccines, were introduced to enhance and prolong immune protection. However, underlying mechanisms humoral cellular immunity induced by homologous versus heterologous regimens remain incompletely understood. This study aimed elucidate responses, including B cell, plasmacytoid dendritic cell (pDC), T activation, following booster vaccination. Methods In a longitudinal cohort study, 136 individuals received three different regimens: mRNA, vector-mRNA-mRNA, or vector-vector-mRNA vaccinations. Serum peripheral blood mononuclear cells (PBMCs) collected at multiple time points up 64 weeks after Anti-SARS-CoV-2 IgG titers neutralization capacity against wildtype virus Omicron variant measured using ELISA cPass assays. Cellular was assessed IFN-γ release assays, flow cytometry employed analyze pDC frequencies, viability, activation markers. Functional pDC-mediated evaluated in mixed lymphocyte cultures. Results stabilized high anti-SARS-CoV-2 neutralizing activity across all regimens, group showing highest antibody capacity. Peripheral frequencies markers (MHC class I/II, CD86) significantly upregulated post-booster. pDCs demonstrated enhanced antigen-presenting promoted SARS-CoV-2-specific responses vitro . Despite differences between breakthrough infection rates 25 post-booster comparable cohorts, suggesting compensatory via immunity. Discussion Our findings highlight pivotal role sustaining effective While induce superior robust may balance protection levels infections. underscores importance integrated potential for optimized strategies pDC-targeted vaccine designs long-term emerging variants.

Language: Английский

---

Epidemiological and clinical features of SARS-CoV-2 Omicron variant infection in Quanzhou, Fujian province: a retrospective study

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Dec. 13, 2023

Abstract Epidemiological and clinical data of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (BA.2) admitted to three designated hospitals in Quanzhou City, Fujian Province, China, were collected analyzed. Overall, 2,541 BA.2, comprising 1,060 asymptomatic, 1,287 mild, 194 moderate infections, enrolled. The percentage infections was higher aged ≥ 60 years than those < 18 18–59 years. median hospitalization duration 17 days. Among the patients, 43.52% had a clear history close contact. vaccination rate 87.92%, asymptomatic vaccinated unvaccinated patients. Moreover, underlying diseases, including hypertension diabetes mellitus, more without diseases. most common manifestations fever, dry cough, sore throat. albumin-to-globulin (A/G) ratio lymphocyte count decreased cases mild while procalcitonin, erythrocyte sedimentation rate, interleukin-6, D-dimer, C4 levels increased. Advanced age, non-vaccination, comorbid diseases high-risk factors for disease progression However, dynamic monitoring blood routine parameters, A/G ratio, inflammatory indicators facilitated prediction progression.

Language: Английский

---